Alector Inc

NASDAQ:ALEC   3:59:59 PM EDT
16.85
+1.31 (+8.43%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.45B
Current PEN/A
Forward PE N/A
2yr Forward PE N/A
See more stats
Estimates Current Quarter
Revenue$8.33 Million
Adjusted EPS-$0.65
See more estimates
10-Day MA$15.88
50-Day MA$14.33
200-Day MA$18.48
See more pivots

Alector, Inc. Stock, NASDAQ:ALEC

151 OYSTER POINT BLVD., SUITE 300, SOUTH SAN FRANCISCO, CA 94080
United States of America
Phone: 415-231-5660
Number of Employees: 78

Description

Alector, Inc., a clinical stage biotechnology company, focuses on developing therapies that harness the immune system to cure neurodegenerative diseases. Its products in Phase I clinical trial include AL001, a humanized recombinant monoclonal antibody for the treatment of frontotemporal dementia; and AL002 for the treatment of Alzheimer's disease. The company's preclinical stage products comprise AL101 for the treatment of multiple neurodegenerative disorders; and AL003 for the treatment of Alzheimer's disease. It also has 10 programs under research and development stage. The company was founded in 2013 and is headquartered in South San Francisco, California.